Interleukin-33 biology with potential insights into human diseases

Nature Reviews Rheumatology

Volumn 7, Issue 6, 2011, Pages 321-329

  Palmer, Gaby ^a   Gabay, Cem ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CXCR2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1R ACCESSORY PROTEIN; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; ST2 RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

AIRWAY; AIRWAY INFLAMMATION; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTHRITIS; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EOSINOPHIL; FIBROSIS; HEART PROTECTION; HOST RESISTANCE; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; MACROPHAGE ACTIVATION; MAST CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SMOOTH MUSCLE FIBER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; ASTHMA; COLITIS, ULCERATIVE; HUMANS; INTERLEUKINS; MICE;

EID: 79958086613     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.53     Document Type: Review

References (118)

1. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005). (Pubitemid 41587888)
2. Moussion, C., Ortega, N. & Girard, J. P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 3, e3331 (2008).
3. Carriere, V. et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl Acad. Sci. USA 104, 282-287 (2007). (Pubitemid 46068023)
4. Roussel, L., Erard, M., Cayrol, C. & Girard, J. P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 9, 1006-1012 (2008).
5. Cayrol, C. & Girard, J. P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl Acad. Sci. USA 106, 9021-9026 (2009).
6. Talabot-Ayer, D., Lamacchia, C., Gabay, C. & Palmer, G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284, 19420-19426 (2009).
7. Lüthi, A. U. et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98 (2009).
8. Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581-18586 (2010).
9. Lingel, A. et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 17, 1398-1410 (2009).
10. Baekkevold, E. S. et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79 (2003). (Pubitemid 36759592)
11. Kuchler, A. M. et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am. J. Pathol. 173, 1229-1242 (2008).
12. Palmer, G. et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749 (2009).
13. Sponheim, J. et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177, 2804-2815 (2010).
14. Ohno, T. et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 183, 7890-7897 (2009).
15. Hayakawa, M. et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem. Biophys. Res. Commun. 387, 218-222 (2009).
16. Ali, S., Nguyen, D. Q., Falk, W. & Martin, M. U. Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem. Biophys. Res. Commun. 391, 1512-1516 (2010).
17. Nile, C. J., Barksby, E., Jitprasertwong, P., Preshaw, P. M. & Taylor, J. J. Expression and regulation of interleukin-33 in human monocytes. Immunology 130, 172-180 (2010).
18. Matsuyama, Y. et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J. Rheumatol. 37, 18-25 (2010).
19. Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J. & Kuchler, A. M. Interleukin-33- cytokine of dual function or novel alarmin? Trends Immunol. 30, 227-233 (2009).
20. Lamkanfi, M. & Dixit, V. M. IL-33 raises alarm. Immunity 31, 5-7 (2009).
21. Hudson, C. A. et al. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 84, 631-643 (2008).
22. Kobori, A. et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J. Gastroenterol. 45, 999-1007 (2010).
23. H2-type responses. J. Immunol. doi:10.4049/ jimmunol.1003020.
24. Keller, M., Ruegg, A., Werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831 (2008). (Pubitemid 351312798)
25. Prefontaine, D. et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J. Immunol. 183, 5094-5103 (2009).
26. H2 driven enteritis. Proc. Natl Acad. Sci. USA 107, 8017-8022 (2010).
27. Prefontaine, D. et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 125, 752-754 (2010).
28. Wood, I. S., Wang, B. & Trayhurn, P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem. Biophys. Res. Commun. 384, 105-109 (2009).
29. Reh, D. D., Wang, Y., Ramanathan, M. Jr. & Lane, A. P. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am. J. Rhinol. Allergy 24, 105-109 (2010).
30. Shimosato, T. et al. CpG oligodeoxynucleotides induce strong up-regulation of interleukin 33 via Toll-like receptor 9. Biochem. Biophys. Res. Commun. 394, 81-86 (2010).
31. Oboki, K., Ohno, T., Kajiwara, N., Saito, H. & Nakae, S. IL-33 and IL-33 receptors in host defense and diseases. Allergol. Int. 59, 143-160 (2010).
32. Trajkovic, V., Sweet, M. J. & Xu, D. T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 15, 87-95 (2004). (Pubitemid 38523333)
33. Bergers, G., Reikerstorfer, A., Braselmann, S., Graninger, P. & Busslinger, M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 13, 1176-1188 (1994). (Pubitemid 24074724)
34. Li, H. et al. The cloning and nucleotide sequence of human ST2L cDNA. Genomics 67, 284-290 (2000). (Pubitemid 30651029)
35. Hayakawa, H., Hayakawa, M., Kume, A. & Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 282, 26369-26380 (2007). (Pubitemid 47443815)
36. Yanagisawa, K., Tsukamoto, T., Takagi, T. & Tominaga, S. Murine ST2 gene is a member of the primary response gene family induced by growth factors. FEBS Lett. 302, 51-53 (1992).
37. Kumar, S., Tzimas, M. N., Griswold, D. E. & Young, P. R. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem. Biophys. Res. Commun. 235, 474-478 (1997). (Pubitemid 27326503)
38. Weinberg, E. O. et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106, 2961-2966 (2002). (Pubitemid 35424749)
39. Tago, K. et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun. 285, 1377-1383 (2001). (Pubitemid 32912936)
40. Ali, S. et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl Acad. Sci. USA 104, 18660-18665 (2007). (Pubitemid 350210753)
41. Chackerian, A. A. et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179, 2551-2555 (2007).
42. Palmer, G. et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 42, 358-364 (2008).
43. Ho, L. H. et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcåRI signals. J. Leukoc. Biol. 82, 1481-1490 (2007). (Pubitemid 350276960)
44. Pecaric-Petkovic, T., Didichenko, S. A., Kaempfer, S., Spiegl, N. & Dahinden, C. A. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113, 1526-1534 (2009).
45. Yagami, A. et al. IL-33 mediates inflammatory responses in human lung tissue cells. J. Immunol. 185, 5743-5750 (2010).
46. H2 cytokine IL-33: implications for allergic inflammation. Cell. Mol. Immunol. 7, 26-34 (2010).
47. Yndestad, A. et al. Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. Int. J. Biochem. Cell Biol. 42, 263-272 (2010).
48. Tare, N. et al. KU812 cells provide a novel in vitro model of the human IL-33/ST2L axis: functional responses and identification of signaling pathways. Exp. Cell Res. 316, 2527-2537 (2010).
49. Sanada, S. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007). (Pubitemid 46871338)
50. Funakoshi-Tago, M. et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell. Signal. 20, 1679-1686 (2008).
51. Funakoshi-Tago, M., Tago, K., Sato, Y., Tominaga, S. I. & Kasahara, T. JAK2 is an important signal transducer in IL-33-induced NF-êB activation. Cell. Signal. 23, 363-370 (2010).
52. H2 immune response. J. Immunol. 182, 2601-2609 (2009).
53. Drube, S. et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 115, 3899-3906 (2010).
54. + monocytes. Cell. Mol. Life Sci. 67, 3883-3892 (2010).
55. Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304 (2007). (Pubitemid 46480961)
56. Ivashkiv, L. B. A signal-switch hypothesis for cross-regulation of cytokine and TLR signalling pathways. Nat. Rev. Immunol. 8, 816-822 (2008).
57. Smith, D. E. The biological paths of IL-1 family members IL-18 and IL-33. J. Leukoc. Biol. 89, 383-392 (2010).
58. Iikura, M. et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest. 87, 971-978 (2007). (Pubitemid 47429189)
59. Moulin, D. et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40, 216-225 (2007). (Pubitemid 350213434)
60. H2 cells. Eur. J. Immunol. 37, 2779-2786 (2007). (Pubitemid 47578297)
61. + T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181, 4780-4790 (2008).
62. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K. & Kita, H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490 (2008). (Pubitemid 351787349)
63. H2 cells, iNKT and NK cells. Int. Immunol. 20, 1019-1030 (2008).
64. Suzukawa, M. et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J. Immunol. 181, 5981-5989 (2008).
65. H1 cells. Proc. Natl Acad. Sci. USA 106, 13463-13468 (2009).
66. H2 cytokines from basophils via a MyD88- and p38á-dependent pathway. J. Leukoc. Biol. 86, 769-778 (2009).
67. Schneider, E. et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J. Immunol. 183, 3591-3597 (2009).
68. + hemopoietic progenitor cells are potent effectors of allergic inflammation. J. Allergy Clin. Immunol. 123, 472-478 (2009).
69. H2-type response. J. Allergy Clin. Immunol. 123, 1047-1054 (2009).
70. Espinassous, Q. et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J. Immunol. 183, 1446-1455 (2009).
71. Kurowska-Stolarska, M. et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183, 6469-6477 (2009).
72. H2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-ã production. Eur. J. Immunol. 39, 1046-1055 (2009).
73. Kim, W. et al. A novel method for procuring a large quantity of mature murine eosinophils in vivo. J. Immunol. Methods 363, 90-94 (2010).
74. Schulze, J. et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res. doi:10.1002/jbmr.269.
75. Joshi, A. D. et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 11, 52 (2010).
76. Humphreys, N. E., Xu, D., Hepworth, M. R., Liew, F. Y. & Grencis, R. K. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180, 2443-2449 (2008).
77. Pushparaj, P. N. et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl Acad. Sci. USA 106, 9773-9778 (2009).
78. Matsuba-Kitamura, S. et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int. Immunol. 22, 479-489 (2010).
79. H2-type immune deviation. Transplantation 89, 1189-1197 (2010).
80. Rankin, A. L. et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J. Immunol. 184, 1526-1535 (2010).
81. Hazlett, L. D. et al. IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 51, 1524-1532 (2010).
82. Stolarski, B., Kurowska-Stolarska, M., Kewin, P., Xu, D. & Liew, F. Y. IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 185, 3472-3480 (2010).
83. Kondo, Y. et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20, 791-800 (2008). (Pubitemid 351791523)
84. Xu, D. et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl Acad. Sci. USA 105, 10913-10918 (2008).
85. Verri, W. A. Jr. et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc. Natl Acad. Sci. USA 105, 2723-2728 (2008). (Pubitemid 351520580)
86. Verri, W. A. Jr. et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 69, 1697-1703 (2010).
87. Xu, D. et al. IL-33 exacerbates autoantibody-induced arthritis. J. Immunol. 184, 2620-2626 (2010).
88. Masamune, A. et al. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G821-G832 (2010).
89. H2 effector function. Proc. Natl Acad. Sci. USA 95, 6930-6935 (1998). (Pubitemid 28278084)
90. Coyle, A. J. et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895-902 (1999). (Pubitemid 29480818)
91. Hoshino, K. et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J. Exp. Med. 190, 1541-1548 (1999).
92. Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069-1076 (2000).
93. H2-type immune response following infection with Nippostrongylus brasiliensis. Eur. J. Immunol. 30, 1929-1938 (2000). (Pubitemid 30456189)
94. H2 cells negatively regulates allergic pulmonary inflammation. Eur. J. Immunol. 37, 1302-1312 (2007). (Pubitemid 46925314)
95. Zhiguang, X. et al. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Immunol. Lett. 131, 159-165 (2010).
96. Leung, B. P., Xu, D., Culshaw, S., McInnes, I. B. & Liew, F. Y. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 173, 145-150 (2004). (Pubitemid 38797335)
97. Saleh, H. et al. Interleukin-33, a target of parathyroid hormone and oncostatin M, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology doi:10.1210/ en.2010-1268.
98. Saidi, S. et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 53, 347-354 (2011).
99. Jones, L. A. et al. IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur. J. Immunol. 40, 426-436 (2010).
100. Wieland, C. W., van Der Windt, G. J., Florquin, S., McKenzie, A. N. & van Der Poll, T. ST2 deficient mice display a normal host defense against pulmonary infection with Mycobacterium tuberculosis. Microbes Infect. 11, 524-530 (2009).
101. Alves-Filho, J. C. et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16, 708-712 (2010).
102. Choi, Y. S. et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 114, 3117-3126 (2009).
103. Miller, A. M. et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339-346 (2008). (Pubitemid 351281600)
104. McLaren, J. E. et al. IL-33 reduces macrophage foam cell formation. J. Immunol. 185, 1222-1229 (2010).
105. Seki, K. et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ. Heart Fail. 2, 684-691 (2009).
106. Sakashita, M. et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin. Exp. Allergy 38, 1875-1881 (2008).
107. Mu, R. et al. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J. Rheumatol. 37, 2006-2013 (2010).
108. Talabot-Ayer, D. et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine doi:10.1016/j.jbspin.2011. 02.011.
109. Mok, M. Y. et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 49, 520-527 (2010).
110. Yang, Z., Liang, Y., Xi, W., Li, C. & Zhong, R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin. Exp. Med. doi:10.1007/ s10238-010-0115-4.
111. Manetti, M. et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann. Rheum. Dis. 69, 598-605 (2010).
112. Sahlander, K., Larsson, K. & Palmberg, L. Increased serum levels of soluble ST2 in birch pollen atopics and individuals working in laboratory animal facilities. J. Occup. Environ. Med. 52, 214-218 (2010).
113. Oshikawa, K. et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respir. Crit. Care Med. 164, 277-281 (2001). (Pubitemid 34001295)
114. Brunner, M. et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 30, 1468-1473 (2004). (Pubitemid 38951733)
115. Shimpo, M. et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190 (2004). (Pubitemid 38625395)
116. Shah, R. V. & Januzzi, J. L. Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr. Heart Fail. Rep. 7, 9-14 (2010).
117. Hoogerwerf, J. J. et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 36, 630-637 (2010).
118. Oppenheim, J. J. & Yang, D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365 (2005). (Pubitemid 40848537)